Should You Request "Breakthrough" Status? Sponsors, FDA Give Their Advice
Executive Summary
Companies need to be selective in seeking the designation and certain that they’ll be able to keep up with the accelerated pace of development and manufacturing expected under the expedited pathway.
You may also be interested in...
FDA Offers Clues, But No Clear Standards, On "Breakthrough"-Worthiness
Although officials say “breakthrough therapies” are “transformative” treatments that “hit you in the face” with their efficacy, the agency has yet to release clear guidelines to help industry determine when a product is worthy of the coveted designation.
Beyond "Breakthrough": FDA, Industry See Benefits For Drugs Outside Expedited Pathway
Pharmaceutical manufacturers and FDA have enthusiastically embraced the “breakthrough therapy” program as a way to more quickly bring new drugs with substantial effects to patients in need. With two years of program experience now under their belts, agency and industry representatives talk about learnings and best practices that could be applied to the development and review of drugs outside the program.
J&J’s Talc Subsidiary Not ‘Financially Distressed’ Enough For Bankruptcy – Third Circuit
The J&J company holding the firm’s liabilities relating to talc litigation, which declared bankruptcy in 2021 shortly after its formation, had its Chapter 11 petition denied by the Third Circuit on 30 January. Attorneys weigh in on the implications for J&J and wider industry.